Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27348979 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL29416299 | 0.88 | KDM4E (0.70) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL68952 | 0.88 | KDM4E (0.70) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL31364268 | 0.85 | KDM4C (0.47) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL28257185 | 0.84 | LMNA (0.47) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL28257295 | 0.81 | LMNA (0.44) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL17462368 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL26132704 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL8123257 | 0.80 | EGFR (0.41) | ALDH1A1KDM4EGLAGAALMNA | |
| SCHEMBL28101840 | 0.80 | TDP1 (0.56) | ALDH1A1KDM4EGLAGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642763-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | claimed |
| WO-2024141534-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | claimed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4642763-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024141534-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | ALDH1A1 1607/4885KDM4E 2467/4885GLA 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.